Your browser doesn't support javascript.
loading
Relationship Between Statin-associated Muscle Symptoms, Serum Vitamin D and Low-density Lipoprotein Cholesterol - A Cross-sectional Study.
Kaur, Harsheen; Singh, Jagjit; Kashyap, Jeet Ram; Rohilla, Ravi; Singh, Harmanjit; Jaswal, Shivani; Kumar, Rajiv.
Afiliación
  • Kaur H; MBBS Student, Government Medical College and Hospital, Chandigarh, India.
  • Singh J; Department of Pharmacology, Government Medical College and Hospital, Chandigarh, India.
  • Kashyap JR; Department of Cardiology, Government Medical College and Hospital, Chandigarh, India.
  • Rohilla R; Department of Community Medicine, Government Medical College and Hospital, Chandigarh, India.
  • Singh H; Department of Pharmacology, Government Medical College and Hospital, Chandigarh, India.
  • Jaswal S; Department of Biochemistry, Government Medical College and Hospital, Chandigarh, India.
  • Kumar R; Department of Pharmacology, Government Medical College and Hospital, Chandigarh, India.
Eur Endocrinol ; 16(2): 137-142, 2020 Oct.
Article en En | MEDLINE | ID: mdl-33117445
INTRODUCTION: Statin-associated muscle symptoms (SAMS) can lead to medication non-adherence among statin users. There is a complex relationship between SAMS, vitamin D and low-density lipoprotein cholesterol (LDL-C). The objective of this study was to evaluate the relationship between vitamin D, LDL-C and occurrence of SAMS. METHODS: This was a cross-sectional study in patients using statins. Thorough patient histories were taken, a clinical examination was conducted and SAMS were recorded. Levels of vitamin D, creatine phosphokinase (CPK) and LDL-C were measured. These parameters were compared amongst statin users with SAMS and those without SAMS. Levels of vitamin D and LDL-C were converted into percentiles and their relationship with SAMS was evaluated in terms of odds ratio. Receiver operating characteristics (ROC) were drawn, taking vitamin D and LDL-C as predictors of SAMS. RESULTS: A total of 121 statin users were enrolled in this study. Thirty-eight patients (31.4%) presented with SAMS. Significantly lower levels of serum vitamin D were observed amongst statin users with SAMS compared with those without SAMS (19.8 ± 9.67 ng/mL versus 25.0 ± 14.6 ng/mL; 95% confidence interval -10.4 to -0.07; p=0.04). With vitamin D levels less than or equal to 5th, 10th and 25th percentile, the chances of occurrence of SAMS were significantly higher, but not at the 50th percentile (corresponding vitamin D level of 20.21 ng/mL). LDL-C did not show any conclusive relationship with SAMS. ROC curves showed a significant discrimination for vitamin D levels, but not for LDL-C. CONCLUSION: Statin users with low levels of vitamin D are at increased risk of developing SAMS. However, LDL-C status of statin users failed to predict any meaningful association with SAMS. Given the small sample size of this study, these results should be regarded as preliminary.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Eur Endocrinol Año: 2020 Tipo del documento: Article País de afiliación: India

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Eur Endocrinol Año: 2020 Tipo del documento: Article País de afiliación: India